亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

医学 偏头痛 安慰剂 双盲 临床试验 传统医学 内科学 药理学 替代医学 病理
作者
Shengyuan Yu,Byung–Kun Kim,Aihong Guo,Manho Kim,Mingjie Zhang,Zhen Wang,Jianguang Liu,Heui‐Soo Moon,Ge Tan,Qian Yang,Donnie McGrath,Michael Hanna,David Stock,Gao Yanfei,Robert Croop,Zhihong Lu
出处
期刊:Lancet Neurology [Elsevier]
卷期号:22 (6): 476-484 被引量:17
标识
DOI:10.1016/s1474-4422(23)00126-6
摘要

No acute treatments targeting calcitonin gene-related peptide (CGRP) have been approved for use in China or South Korea. We aimed to compare the efficacy and safety of rimegepant-an orally administered small molecule CGRP antagonist-with placebo in the acute treatment of migraine among adults in these countries.This double-blind, randomised, placebo-controlled, multicentre phase 3 trial was done at 86 outpatient clinics at hospitals and academic medical centres (73 in China and 13 in South Korea). Participants were adults (≥18 years) with at least a 1-year history of migraine who had two to eight moderate or severe attacks per month and fewer than 15 headache days per month within the 3 months before the screening visit. Participants were randomly assigned (1:1) to 75 mg rimegepant or placebo to treat a single migraine attack of moderate or severe pain intensity. Randomisation was stratified by the use of preventive medication and by country. The allocation sequence was generated and implemented by study personnel using an interactive web-response system accessed online from each study centre. All participants, investigators, and the sponsor were masked to treatment assignment. The coprimary endpoints of freedom from pain and freedom from the most bothersome symptom (nausea, phonophobia, or photophobia) 2 h after dosing were assessed in the modified intention-to-treat (mITT) population (randomly assigned participants who took study medication for a migraine attack of moderate or severe pain intensity, and provided at least one efficacy datapoint after treatment) using Cochran-Mantel Haenszel tests. Safety was assessed in all participants who received rimegepant or placebo. The study is registered with ClinicalTrials.gov, number NCT04574362, and is completed.1431 participants were randomly assigned (716 [50%] to rimegepant and 715 [50%] to placebo). 668 (93%) participants in the rimegepant group and 674 (94%) participants in the placebo group received treatment. 1340 participants were included in the mITT analysis (666 [93%] in the rimegepant group and 674 [94%] in the placebo group). 2 h after dosing, rimegepant was superior to placebo for pain freedom (132 [20%] of 666 vs 72 [11%] of 674, risk difference 9·2, 95% CI 5·4-13·0; p<0·0001) and freedom from the most bothersome symptom (336 [50%] of 666 participants vs 241 [36%] of 674 participants, 14·8, 9·6-20·0; p<0·0001). The most common (≥1%) adverse events were protein in urine (8 [1%] of 668 participants in the rimepegant group vs 7 [1%] of 674 participants in the placebo group), nausea (7 [1%] of 668 vs 18 [3%] of 674), and urinary tract infection (5 [1%] of 668 vs 8 [1%] of 674). There were no rimegepant-related serious adverse events.Among adults living in China or South Korea, a single dose of 75 mg rimegepant was effective for the acute treatment of migraine. Safety and tolerability were similar to placebo. Our findings suggest that rimegepant might be a useful new addition to the range of medications for the acute treatment of migraine in China and South Korea, but further studies are needed to support long-term efficacy and safety and to compare rimegepant with other medications for the acute treatment of migraine in this population.BioShin Limited.For the Chinese and Korean translations of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wang完成签到 ,获得积分20
5秒前
8秒前
13秒前
科研通AI2S应助yang采纳,获得10
27秒前
NS完成签到,获得积分10
2分钟前
zsmj23完成签到 ,获得积分0
2分钟前
17852573662完成签到,获得积分10
2分钟前
3分钟前
隐形曼青应助FUNG采纳,获得10
3分钟前
火山完成签到 ,获得积分10
3分钟前
3分钟前
5分钟前
5分钟前
浮曳发布了新的文献求助10
5分钟前
zhouleiwang举报认真做科研求助涉嫌违规
5分钟前
5分钟前
司空天德发布了新的文献求助10
5分钟前
小蘑菇应助科研通管家采纳,获得10
5分钟前
李健应助浮曳采纳,获得10
5分钟前
6分钟前
6分钟前
6分钟前
7分钟前
Wu发布了新的文献求助10
7分钟前
FUNG发布了新的文献求助10
7分钟前
Wu完成签到,获得积分10
7分钟前
深情安青应助科研通管家采纳,获得10
7分钟前
7分钟前
8分钟前
8分钟前
zhouleiwang完成签到,获得积分10
8分钟前
东方傲儿发布了新的文献求助10
8分钟前
jason完成签到,获得积分10
8分钟前
香蕉觅云应助东方傲儿采纳,获得10
8分钟前
8分钟前
jason发布了新的文献求助10
8分钟前
9分钟前
9分钟前
天天快乐应助mochi采纳,获得10
10分钟前
10分钟前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
宽禁带半导体紫外光电探测器 388
Case Research: The Case Writing Process 300
Global Geological Record of Lake Basins 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3142703
求助须知:如何正确求助?哪些是违规求助? 2793574
关于积分的说明 7807032
捐赠科研通 2449892
什么是DOI,文献DOI怎么找? 1303518
科研通“疑难数据库(出版商)”最低求助积分说明 626959
版权声明 601328